Engineering group DPS and its US-based architectural partner Tria have been selected to provide architectural, engineering and project management services for a new $110M GMP mRNA clinical manufacturing facility in Norwood, Massachusetts.
The contract, awarded by biotechnology firm Moderna Therapeutics, will include the provision of full architectural and engineering design for the 18,600sq m facility.
The companies will also be responsible for the construction management oversight, commissioning, qualification and validation and procurement services.
Tria is designing the clinical labs, offices, employee facilities and conference centre for the project.
DPS CEO Frank Keogh said: "This is a significant contract win for DPS and builds on the strong relationship we have developed with Moderna. We are proud to be supporting Moderna with this major investment in Norwood. This project demonstrates DPS's ability to bid for and win large-scale capital investment design projects in the US."
Construction on the new facility is set to start in October 2016 and be completed in early 2018.